8-K: Strata Critical Medical Completes Passenger Business Sale, Rebrands for Medical Logistics Focus

Strata Critical Medical, formerly Blade Air Mobility, has completed the sale of its Passenger business to Joby Aero, Inc. and rebranded to focus entirely on medical logistics.

Summary

• Blade Air Mobility, Inc. has officially changed its name to Strata Critical Medical, Inc. and will trade under the new Nasdaq ticker symbol SRTA, effective August 29, 2025.
• The company completed the sale of its Passenger business to Joby Aero, Inc., a subsidiary of Joby Aviation, Inc., on August 29, 2025.
• The initial purchase price for the Passenger business was approximately $76.0 million, paid in 5,325,585 shares of Joby Aviation's common stock, valued at $14.27 per share as of August 28, 2025.
• Strata Critical Medical may receive up to an additional $35.0 million in contingent consideration based on employee retention and financial performance targets over 12 to 18 months, plus a release of up to $10.0 million in indemnity holdbacks.
• The company's strategic focus is now 100% on organ logistics and other medical services, with the Passenger business to be reported as discontinued operations from Q3 2025.
• New financial guidance for fiscal year 2025 projects revenue of $160-170 million and double-digit Adjusted EBITDA.
• Adjusted unallocated corporate expenses and software development costs are expected to decrease to a quarterly run rate of approximately $3.5 million in Q4 2025.
• Strata entered into a Restrictive Covenant Agreement with Joby Aviation, including non-solicitation and non-compete clauses for 8 years (short-distance) and 3 years (jet charter), with exceptions for medical transport and B2B aviation sales.
• A Commercial Agreement grants Joby Buyer the right to provide medical transport services to Strata for 8 years and establishes a right of first refusal for Joby to provide eVTOL medical transport services under competitive terms.
• The Board of Directors expanded from eight to ten members, with Melissa Tomkiel and William Heyburn appointed as directors in addition to their Co-CEO roles.
• John Borthwick and Kenneth Lerer resigned from the Board of Directors, effective upon the closing of the transaction.

Sentiment

Score: 8

Explanation: The filing indicates a strong strategic pivot with clear financial benefits and a focused growth path in a resilient industry. The divestiture of a potentially underperforming segment and the capital infusion, along with positive financial guidance for the new core business, are significant positives. The non-compete clauses are a minor negative given the strategic shift.

Positives

• The divestiture allows for a 100% focus on the rapidly growing, contractual, and macro-non-correlated marketplaces for organ logistics and other medical services.
• The company is well-funded to pursue organic growth, strategic partnerships, and acquisitions in the medical services and logistics sector.
• The updated 2025 financial guidance projects revenue of $160-170 million and double-digit Adjusted EBITDA, indicating a healthy outlook for the focused business.
• Expected decrease in adjusted unallocated corporate expenses and software development costs to a quarterly run rate of approximately $3.5 million in Q4 2025 suggests improved operational efficiency.
• The Commercial Agreement with Joby provides a potential long-term partnership for medical transport services and future eVTOL opportunities.
• The initial consideration of $76.0 million in Joby Aviation stock, with potential for an additional $45.0 million, strengthens the company's financial position.

Negatives

• The Restrictive Covenant Agreement imposes non-compete obligations on Strata for 8 years in short-distance passenger air transport and 3 years in jet charter services, limiting future expansion into these areas.
• The contingent consideration and indemnity holdbacks are subject to certain targets and Joby Buyer's election, introducing some uncertainty regarding the full realization of the potential $45.0 million.

Risks

• Unexpected costs, charges, or expenses resulting from the recently completed divestiture.
• Failure to realize the anticipated efficiencies and benefits of the transaction.
• Fluctuations in the value of any equity issued to Strata in the transaction (Joby Aviation common stock).
• Continued incurrence of significant losses.
• Failure of the markets for offerings to grow as expected, or at all.
• Ability to successfully enter new markets and launch new routes and services.
• Adverse publicity stemming from accidents involving small aircraft, helicopters, or charter flights, particularly those involving third-party operators.
• Challenges related to any change to the ownership of aircraft.
• Effects of competition.
• Harm to reputation and brand.
• Ability to provide high-quality customer support.
• Ability to maintain a high daily aircraft usage rate.
• Changes in economic conditions.
• Impact of natural disasters, outbreaks, pandemics, economic, social, weather, geopolitical, growth constraints, and regulatory conditions on metropolitan areas and airports.
• Effects of climate change, including potential increased impacts of severe weather and regulatory activity.
• Availability of aircraft fuel.
• Ability to address system failures, defects, errors, or vulnerabilities in technology systems.
• Interruptions or security breaches of information technology systems.
• Placements within mobile applications.
• Ability to protect intellectual property rights.
• Use of open source software.
• Ability to expand and maintain infrastructure network.
• Ability to access additional funding.
• Ability to identify, complete, and successfully integrate future acquisitions.
• Ability to manage growth.
• Increases in insurance costs or reductions in insurance coverage.
• Loss of key members of the management team.
• Ability to maintain company culture.
• Reliance on contractual relationships with certain transplant centers and Organ Procurement Organizations.
• Effects of fluctuating financial results.
• Reliance on third-party operators and their availability or disruptions.
• Increases in insurance costs or reductions in insurance coverage for third-party aircraft operators.
• Possibility that third-party aircraft operators may illegally, improperly, or otherwise inappropriately operate branded aircraft.
• Reliance on third-party web service providers.
• Changes in the regulatory environment and regulatory obstacles in local governments.
• Expansion of domestic and foreign privacy and security laws and environmental regulations.
• Ability to remediate any material weaknesses or maintain internal controls over financial reporting and effective internal controls and disclosure controls.
• Changes in the fair value of warrants.
• Other factors beyond control.

Future Outlook

The company is updating its 2025 financial guidance to reflect the Passenger business divestiture, projecting revenue of $160-170 million and double-digit Adjusted EBITDA. Adjusted unallocated corporate expenses and software development costs are expected to decrease to a quarterly run rate of approximately $3.5 million in Q4 2025. The strategic focus is now entirely on medical services and logistics, with plans for organic growth, strategic partnerships, and acquisitions in this sector. A right of first refusal for Joby to provide eVTOL medical transport services in new U.S. regions is established, along with exclusive negotiation for eVTOL aircraft purchases/leases from Joby under competitive terms.

Management Comments

• "Our re-branding as Strata Critical Medical reflects the Company's now 100% focus on the rapidly growing, contractual, and macro-non-correlated marketplaces for organ logistics and other medical services." Melissa Tomkiel, Co-CEO and General Counsel.
• "We've built the industry-leading organ transplant logistics and services platform, delivering rapid response times and cost efficiency while benefiting from the redundancy and unmatched scale of our coast-to-coast asset-light aircraft network." Melissa Tomkiel, Co-CEO and General Counsel.
• "Strata's experience and track record providing mission-critical logistics to the organ transplant community provides the foundation for our growth plan in medical services and logistics more broadly." Will Heyburn, Co-CEO and CFO.
• "Our one-call logistics solution, where we procure a variety of additional services from third-parties on behalf of our customers, gives us a unique vantage point into a multitude of growth opportunities, which we will continue to pursue through organic growth, strategic partnerships and acquisitions, for which we are very well funded." Will Heyburn, Co-CEO and CFO.

Industry Context

This announcement signifies a complete strategic pivot for the company, moving away from the competitive and capital-intensive passenger air mobility sector towards the specialized and growing market of medical logistics, particularly organ transport. This shift aligns with a broader trend of companies seeking niche markets with higher barriers to entry, more stable revenue streams, and less exposure to consumer discretionary spending. The focus on 'macro-non-correlated' marketplaces suggests a move towards resilience against economic downturns. The partnership with Joby Aero, a leader in eVTOL technology, positions Strata to potentially leverage future advancements in air mobility for medical applications, differentiating itself from traditional logistics providers.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: The strategic shift to medical logistics, coupled with a significant cash and stock infusion from the sale, is expected to enhance long-term shareholder value by focusing on a more stable and growing market. The updated financial guidance for the core business suggests improved profitability. Changes in corporate governance aim to strengthen oversight.
• **Employees**: The company's focus on medical services and logistics provides clarity on future employment opportunities within the new strategic direction. Employee retention targets tied to contingent consideration from the sale incentivize continued performance.
• **Customers (Medical Services)**: The company's 100% focus on medical logistics is expected to lead to enhanced service quality, innovation, and efficiency in organ transport and other medical services.
• **Customers (Former Passenger Business)**: These customers will now be served by Joby Aero, Inc., indicating a seamless transition for their air mobility needs.
• **Joby Aviation**: Becomes a significant partner and shareholder, with a commercial agreement for medical transport services and a right of first refusal for eVTOL services, aligning interests in future air mobility solutions.

Next Steps

• Report the Passenger business as discontinued operations in the Q3 2025 earnings report.
• Host an investor day in Fall 2025 to provide more information on the company's strategy and outlook.
• Continue to pursue organic growth, strategic partnerships, and acquisitions in medical services and logistics.
• Cooperate with Joby and negotiate in good faith to amend the Commercial Agreement or enter new agreements for eVTOL medical transport services in new U.S. regions.
• Negotiate exclusively with Joby for eVTOL aircraft purchases or leases if suitable aircraft are available and terms are competitive.

Key Dates

Recommendation

The strategic divestiture of the Passenger business, which was likely a capital-intensive and competitive segment, allows Strata Critical Medical to focus entirely on the high-growth, contractual, and macro-non-correlated medical logistics market. The initial $76.0 million in Joby Aviation stock, with potential for an additional $45.0 million, significantly strengthens the balance sheet and provides a valuable stake in a leading eVTOL company. The updated 2025 financial guidance for the core medical business, projecting double-digit Adjusted EBITDA and substantial revenue, indicates a more profitable and stable operational outlook. The new management structure with Co-CEOs and enhanced corporate governance further supports this positive trajectory. This pivot positions the company for sustained growth and improved financial performance, making it an attractive investment.

Keywords

Medical Logistics, Organ Transplant Logistics, Critical Medical Transport, Strategic Divestiture, Name Change, SEC Filing, 8-K, Joby Aviation, eVTOL, Corporate Governance, Financial Guidance, SRTA